3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Osteosarcoma
1
Melanoma
1
Interventions
Trastuzumab
304
Paclitaxel
257
Cyclophosphamide
251
Docetaxel
238
Capecitabine
175
Letrozole
163
Carboplatin
163
Fulvestrant
145
Doxorubicin
145
Bevacizumab
121
Anastrozole
106
Tamoxifen
102
exemestane
94
Vinorelbine
91
Epirubicin
90
pertuzumab
89
Gemcitabine
84
Lapatinib
80
Albumin-Bound Paclitaxel
74
Radiotherapy
71
pembrolizumab
70
palbociclib
64
130-nm albumin-bound paclitaxel
58
eribulin
56
Cisplatin
55
Everolimus
49
pyrotinib
45
Taxes
44
Goserelin
43
Neoadjuvant Therapy
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Neoplasms
×
glembatumumab vedotin
×
Clear all
NCT01997333
2019-03-08
METRIC
Celldex Therapeutics
Phase 2
Completed
327 enrolled
17 charts
NCT01156753
2017-07-02
EMERGE
Celldex Therapeutics
Phase 2
Completed
120 enrolled